FDA nod to Watson Labs’ Rapaflo for BPH’s treatment
The U.S. Food and Drug Administration has approved Watson Laboratories’ Rapaflo (silodosin) capsules for the treatment of symptoms of benign prostatic hyperplasia (BPH). Having high affinity for α-receptors concentrated in the prostate, the blocker binds them to smoothen muscles in the tissues. This relaxes them, improving flow of urine and reducing symptoms of BPH such as retrograde ejaculation, dizziness etc.
- Watson Applies For Approval For Generic Renvela
- Endo Parma introduces treatment for distinct form of bladder cancer
- Endo Pharma reintroduces Valstar
- First Non-Invasive Technology For Treatment Of Uterine Fibroids Awarded MHLW Approval In Japan
